Lancovutide

Drug Profile

Lancovutide

Alternative Names: 2622U90; Duramycin; Moli 1901; PA 48009

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lantibio
  • Developer AOP Orphan Pharmaceuticals AG; Lantibio
  • Class Expectorants; Peptides
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cystic fibrosis; Dry eyes

Most Recent Events

  • 16 Sep 2009 Pharmacokinetics data from a phase I trial in Cystic fibrosis presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 08 Mar 2007 Results from a phase II clinical trial in patients with Cystic fibrosis have been added to the adverse events and Respiratory disoders therapeutic trials sections
  • 17 Jan 2006 Phase-II clinical trials in Cystic fibrosis in Austria (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top